OpenAI Acquires Orchestra Bio to Integrate AI Agents in Drug Development

OpenAI says Orchestra Bio's platform lets scientists and AI agents work together to coordinate drug programs. Its agents can help teams identify how a failed manufacturing batch might affect a clinical-trial timeline and compare ways to respond, leaving decisions to scientists and program leaders. OpenAI aims to connect scientific findings with the work of developing treatments and help new medicines reach patients sooner.